While regulators are open to using Patient-Reported Outcomes (PROs) for drug approval, the oncology community reflexively prioritizes survival data. This cultural bias sees PROs as "softer" endpoints, hindering the approval of drugs based on how patients feel and function.

Don't wait until Phase 3 to think about commercialization. Biotech firms must embed secondary endpoints in Phase 2 trials that capture quality of life and patient journey insights. This data is critical for building a compelling value proposition that resonates with payers and secures market access.

Instead of waiting years for traditional vision preservation data, Complement Therapeutics' trial prospectively uses novel endpoints like ellipsoid zone attenuation and focal microperimetry. These measures are designed to show a signal of efficacy earlier and correlate better with functional outcomes, addressing a key challenge in slowly progressing diseases.

Beyond nearly doubling survival rates, Immuneering emphasizes concrete quality of life improvements, such as a patient regaining the ability to drive. This patient-centric narrative powerfully demonstrates the drug's real-world impact and differentiates it from therapies with grueling side effects.

To be effective, the patient's lived experience cannot remain a "soft narrative." It must be converted into hard data points—like reduced healthcare utilization for payers or influence on treatment pathways for clinicians—to become a decision-making tool they cannot ignore.

Although regulatory trials for relapsing MS focus on relapse rates as a primary endpoint, the CEO identifies "confirmed disability progression" as the most critical outcome for patients and physicians. This secondary endpoint is the true measure of a drug's ability to change the treatment landscape long-term.

Biotech leaders must stop viewing commercialization as a post-approval task. The critical window is Phase 2 clinical trials. By embedding patient journey and quality of life insights into secondary endpoints, companies can build a compelling value proposition for payers and physicians. Waiting until Phase 3 is too late.

While outsiders assume walking is the ultimate recovery goal, NervGen's research reveals that regaining hand function for daily tasks like eating or using a computer is the most vital improvement for patient independence. This highlights the importance of patient-defined quality-of-life endpoints in clinical trials.

During NervGen's End-of-Phase 2 meeting, the FDA emphasized understanding the drug's real-world impact on a patient's daily life, not just the quantitative results of the primary endpoint. This signals a regulatory shift towards a more holistic, patient-centric view of therapeutic benefit in areas of high unmet need.